- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05919108
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. Determine efficacy of neoadjuvant neratinib in combination with endocrine therapy.
SECONDARY OBJECTIVES:
I. Determine additional efficacy outcomes of neoadjuvant neratinib in combination with endocrine therapy.
II. Compare the safety and tolerability of neratinib plus endocrine therapy.
CORRELATIVE OBJECTIVE:
I. Establish HER2-mutant invasive lobular carcinoma (ILC) organoids.
OUTLINE: Patients are randomized to 1 of 2 treatments.
TREATMENT A: Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib orally (PO) daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast magnetic resonance imaging (MRI) prior to surgery.
TREATMENT B: Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
After completion of study treatment, patients are followed up for 4 weeks after study drugs interruption.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Vanderbilt-Ingram Services for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University/ Winship Cancer Institute
-
Principal Investigator:
- Kevin Kalinsky, MD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
Principal Investigator:
- Adam Brufsky, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Vanderbilt University/Ingram Cancer Center
-
Principal Investigator:
- Laura Kennedy, MD, PhD
-
Contact:
- Vanderbilt-Ingram Service for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas, Southwestern
-
Principal Investigator:
- Carlos Arteaga, MD
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Principal Investigator:
- Bora Lim, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Each patient will be entered into this study only if all of these criteria are met:
- Subjects aged 18 years or older at signing of informed consent.
- New diagnosis of clinical stage I-III HR+ histologically-proven (i.e. absent or decreased e-cadherin expression) invasive lobular carcinoma
- Synchronous breast tumors are permitted as long as the synchronous tumor is ER+ and HER2-negative.
- ER+ disease defined as ≥1% estrogen receptor (ER) positive consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines)
- At the time of screening, histologically confirmed cancers in patients with previously documented activating HER2 mutation (see Appendix A) confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory.
- Archival tissue availability (if not available a fresh tumor biopsy will be required) and subject must agree to submission of sample for central testing
- Minimum tumor size of ≥1.5 cm by US, mammogram, MRI imaging, or clinical breast exam
- ECOG performance status 0 or 1
Patients must have adequate hematologic, hepatic, and renal function. All laboratory tests must be obtained within 1 month of study entry. This includes:
- Estimated glomerular filtration rate of ≥50 mL/min
- Albumin ≥ 2.5 g/dL
- ANC ≥1500/mm^3
- Platelet count ≥100,000/mm^3
- HgB ≥ 9 g/dL
- Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)
- AST and ALT ≤ 3 x ULN
- Pre-, peri-, or post-menopausal, confirmed by history or laboratory testing as needed
- Diagnostic biopsy tissue availability with sufficient tumor to permit NGS (if not available, a fresh biopsy will be required)
- No prior treatment for current diagnosis of breast cancer
For patients who are not postmenopausal (women) or surgically sterile (absence of ovaries and/or uterus or vasectomy), agreement to remain abstinent or to use two adequate methods of contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal ligation), during the treatment period and for at least 30 days after the last dose of study treatment. Hormone based oral contraceptives are not allowed on study. Postmenopausal is defined as:
- Age ≥ 55 years
- Age ≤ 55 years and amenorrheic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone and estradiol in the postmenopausal range. Female participants of childbearing potential are eligible to participate if they agree to use a highly effective method of contraception that has a low user dependency consistently and correctly.
Note: The effects of neratinib on the developing fetus are unknown and endocrine therapy is contraindicated in pregnancy. For this reason and because teratogenic effects have been observed in nonclinical studies and neratinib, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation, and for 1 month after the last dose of study medication. Should a woman become pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation and 3.5 months after completion of study treatment.
Exclusion Criteria:
- Evidence of distant metastatic disease
- Synchronous breast cancer that is estrogen receptor negative OR HER2-amplified OR requires treatment with neoadjuvant chemotherapy per the judgement of the treating physician
- Patients harboring ineligible somatic HER2 mutations, such as those that are subclonal in nature or those resulting in the expression of truncated proteins including alterations that result in premature stop codon or a change in reading frame (ie, frame shift mutations).
- Prior endocrine therapy for breast cancer within the last 2 years
- Women who are pregnant, are planning to become pregnant, or are breast-feeding
- Any investigational treatment for the current diagnosis of breast cancer
- HER2 amplification by FISH (HER2:CEP17 ratio >2.0) or IHC (HER2 (3+)
- Hepatic function impairment as defined by AST or ALT > 3x ULN OR total serum bilirubin > 1.5 (in patients with known Gilbert syndrome, a total bilirubin of > 3.0 x ULN or direct bilirubin > 1.5 x ULN)
- Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or Grade ≥2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE version 4.0] diarrhea of any etiology at baseline.
- Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the Investigator's judgment, make the patient inappropriate for this study.
- Known hypersensitivity to any component of the investigational product, required combination therapy, or loperamide.
- Unable or unwilling to swallow tablets.
- Unable or unwilling to complete study procedures such as research biopsies or imaging
- Any medical condition that in the judgement of the co-investigator would impair the patient's ability to complete the planned study therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment A (endocrine therapy)
Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle.
Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo breast surgery during weeks 24-25.
Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery.
Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
|
Undergo collection of blood samples
Undergo endocrine therapy
Undergo breast biopsy
Taken by mouth
Undergo Mammogram
Undergo breast Magnetic Resonance Imaging
Undergo Breast Surgery
|
Experimental: Treatment B (endocrine therapy, neratinib)
Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle.
Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo breast surgery during weeks 24-25.
Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery.
Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
|
Undergo collection of blood samples
Undergo endocrine therapy
Undergo breast biopsy
Taken by mouth
Undergo Mammogram
Undergo breast Magnetic Resonance Imaging
Undergo Breast Surgery
Undergo Ultrasound
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Preoperative endocrine prognostic index score
Time Frame: Up to 5 years
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response rate
Time Frame: Up to 5 years
|
Will be summarized for the entire cohort by response.
|
Up to 5 years
|
Change in Ki67
Time Frame: At 4 weeks
|
At 4 weeks
|
|
Residual cancer burden index
Time Frame: Up to 5 years
|
Will be summarized for the entire cohort by response
|
Up to 5 years
|
Rates of breast conservation therapy
Time Frame: Up to 5 years
|
Will be summarized for the entire cohort by response
|
Up to 5 years
|
Incidence of adverse events (NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
Time Frame: Up to 5 years
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Kennedy, MD, PhD, Vanderbilt University/Ingram Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VICC-NCBRE23172
- NCI-2023-04468 (Registry Identifier: NCI, Clinical Trials Reporting Program)
- 1R01CA273246-01A1 (U.S. NIH Grant/Contract: National Institutes of Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Lobular Carcinoma
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
St. Joseph Hospital of OrangeCompletedStage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast CarcinomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedInvasive Ductal Carcinoma | Invasive Lobular Carcinoma | Ductal CarcinomaUnited States
-
University of UtahRecruitingInvasive Lobular Breast CarcinomaUnited States
-
University of ChicagoActive, not recruitingLung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
Auxilio Mutuo Cancer CenterUnknownInfiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast CarcinomaPuerto Rico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Auxilio Mutuo Cancer CenterSononuclearUnknownLobular Breast Carcinoma | Inflammatory Breast Carcinoma | Invasive Ductal CarcinomaPuerto Rico
Clinical Trials on Biospecimen Collection
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Mayo ClinicRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.RecruitingColorectal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting
-
Mayo ClinicRecruitingEarly Stage Breast Carcinoma | Chemotherapy-Related Nausea and/or VomitingUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruiting